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Abstract 
Background: Electronic health records (EHRs) can provide valuable data for outcomes research. However, unlike 
administrative claims databases, EHRs lack eligibility tables or a standard way to define the benefit coverage period, 
which could lead to underreporting of healthcare utilization or outcomes, and could result in surveillance bias. We 
tested the effect of using a proxy eligibility period (eligibility proxy) when estimating a range of health resource utili‑
zation and outcomes parameters under varying degrees of missing encounter data.
Methods: We applied an eligibility proxy to create a benchmark cohort of chronic obstructive pulmonary disease 
(COPD) patients with 12 months of follow‑up, with the assumption of no missing encounter data. The benchmark 
cohort provided parameter estimates for comparison with 9,000 simulated datasets representing 10–90% of COPD 
patients (by 10th percentiles) with between 1 and 11 months of continuous missing data. Two analyses, one for data‑
sets using an eligibility proxy and one for those without an eligibility proxy, were performed on the 9,000 datasets to 
assess estimator performance under increasing levels of missing data. Estimates for each study variable were com‑
pared with those from the benchmark dataset, and performance was evaluated using bias, percentage change, and 
root‑mean‑square error.
Results: The benchmark dataset contained 6,717 COPD patients, whereas the simulated datasets where the eligibil‑
ity proxy was applied had between 671 and 6,045 patients depending on the percentage of missing data. Parameter 
estimates had better performance when an eligibility proxy based on the first and last month of observed activity 
was applied. This finding was consistent across a range of variables representing patient comorbidities, symptoms, 
outcomes, health resource utilization, and medications, regardless of the measures of performance used. Without the 
eligibility proxy, all evaluated parameters were consistently underestimated.
Conclusion: In a large COPD patient population, this study demonstrated that applying an eligibility proxy to EHR 
data based on the earliest and latest months of recorded activity minimized the impact of missing data in outcomes 
research and improved the accuracy of parameter estimates by reducing surveillance bias. This approach may address 
the problem of missing data in a wide range of EHR outcomes studies.
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Background
Health outcomes research has evolved as the variety of 
available electronic data sources has expanded along with 
growth in health information technology [1]. Electronic 
health records (EHRs) are databases that healthcare pro-
viders use to record patient-related information to track 
care. The increasing availability of these EHRs has pro-
vided a valuable data source for outcomes research [2, 
3]. EHR data can be used in burden-of-illness and clini-
cal outcomes studies, comparative effectiveness research, 
and health technology assessments. Other studies have 
used EHRs from multiple locations to gather clinical 
information about a given study population [2], an appli-
cation analogous to a chart review.
The number of studies using EHRs in health out-
comes research has grown, ranging from only a hand-
ful of studies published in 2000 [2] to over 50 studies 
reporting globally in the years 2010–2011 alone [3]. As 
healthcare providers in multiple countries adopt EHRs 
to record patient care, EHRs are becoming an increas-
ingly important data source for outcomes research and 
for improving healthcare delivery. For example, the US 
Patient-Centered Outcomes Research Institute (PCORI) 
has demonstrated its commitment to supporting EHRs 
in comparative effectiveness research by funding 11 clini-
cal data research networks based on electronic records of 
large integrated care networks, as well as 18 patient-pow-
ered research networks, to collect and curate patient-
provided data in a standardized format [4].
In the US, administrative claims databases, which con-
tain information on patient care that payers use to reim-
burse healthcare providers, are frequently used in health 
outcomes research. A major strength of EHRs in out-
comes research is their ability to capture detailed clinical 
information not available in claims data, such as symp-
toms, biometrics, laboratory test results, and prescribed 
drugs [3, 5, 6]. EHRs can therefore provide a richer 
source of real-world information than claims data regard-
ing disease severity and symptoms, prognosis, treatment 
patterns, and outcomes.
Although EHRS have many advantages, several limi-
tations exist. First, EHRs are subject to technological 
issues that may affect their use for tracking patient care 
and for research. These issues include the need for tech-
nology support such as systems protection and a lack of 
interoperability between EHRs and other data sources, 
which limits the ability to link data across EHR databases 
[5]. Second, EHR data may be erroneous or uninterpret-
able, and are prone to inconsistencies in provider-entered 
data. Unlike claims data, where diagnoses, health ser-
vices performed, and medications are coded in a stand-
ardized manner for reimbursement purposes, EHR data 
vary by provider and by software system used. Some EHR 
information may also be in the form of text notes, which 
may require natural language processing (NLP) before 
being usable for research [5]. Finally, EHR data capture 
patient information only when care is provided within 
the healthcare system. The absence of records does not 
necessarily reflect the absence of an episode of care [5], 
and could represent an absence of a need for healthcare, 
or a missing healthcare encounter if the patient received 
care at a facility that does not contribute data to the EHR 
system.
When conducting research using retrospective data-
bases, researchers define the period of observation (study 
period) during which the study population contributes 
healthcare encounter data. In studies utilizing admin-
istrative claims databases (claims data), only popula-
tion eligible to receive benefits during the study period 
should be included in research [7], and this is typically 
done using eligibility tables (plan enrollment informa-
tion) that list start and end dates for healthcare and drug 
benefits. Using a continuous eligibility period ensures 
that the study period falls within the time of the patient’s 
recorded treatment and that all episodes of care and 
outcomes in the study period are captured via complete 
claims records, provided that the patient’s activity was 
limited to the recording claims source [7]. Unlike claims 
data, EHRs do not provide eligibility tables, and thus out-
comes research using EHRs is subject to the problem of 
missing data due to underreporting of healthcare utiliza-
tion or outcomes rendered at facilities that do not con-
tribute data to the EHR system, which could result in 
surveillance bias.
Our objective was to test the hypothesis that by identi-
fying and applying a proxy eligibility period to EHR data-
set analysis, we could increase the likelihood of obtaining 
complete EHR data on patient care and outcomes. It is 
possible to identify each patient’s earliest (first) and last 
month of receiving medical services in an EHR and to 
then assume that healthcare was continuously received 
and recorded during that ‘active’ period of EHR reporting 
(hereafter “eligibility proxy”). Consequently, the result-
ing estimates for parameters of interest based on the 
data would be expected to have less bias than parameter 
estimates that did not use an eligibility proxy. Although 
missing data and surveillance bias are still concerns in 
any database, we hypothesized that their impact would 
be reduced when an eligibility proxy was applied in EHR 
dataset analysis.
Methods
Patient population, EHR database and study design
Chronic obstructive pulmonary disease (COPD) is an 
irreversible, obstructive lung disease with high morbid-
ity and mortality [8–10]. COPD affects nearly 24 million 
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people in the US and is a leading driver of disease-man-
agement costs that impact the US healthcare system [11], 
thus ensuring a sufficiently large EHR sample size and a 
policy-relevant population for the present study. We con-
ducted a simulation study in a cohort of patients with 
COPD identified in a large, US-based EHR to test the 
effect on parameter estimates of applying an eligibility 
proxy under varying degrees of missing encounter data 
for a range of health resource utilization and outcomes.
We conducted multiple simulations of observational 
data using the Humedica EHR database (An Optum 
Company, Boston, MA, USA). Humedica’s data acquisi-
tion model starts with the providers of care, including 
many prominent Integrated Delivery Networks. Humed-
ica aggregates EHR data directly from providers, inte-
grating data from multiple disparate EHRs from across 
the continuum of care, both inpatient and ambulatory. 
These data capture a comprehensive clinical picture 
that includes medications, laboratory results, vital signs, 
physician notes, diagnoses, procedures, demographics, 
hospitalizations, and outpatient visits. Once aggregated, 
Humedica normalizes, validates, and statistically dei-
dentifies these data for use in clinical research. The data 
are certified as deidentified by an independent statisti-
cal expert following US Health Insurance Portability and 
Accountability Act (HIPAA) statistical deidentification 
rules, and managed according to Humedica’s customer 
data use agreements. Because this study did not involve 
the collection, use, or transmittal of individually identi-
fiable data, Institutional Review Board (IRB) review or 
approval was not required.
Cohort identification and inclusion criteria for the 
benchmark dataset
The study period was January 1, 2007 through December 
31, 2012. The first month ‘active’ was defined as the ear-
liest month with a recorded healthcare encounter in the 
EHR dataset that occurred during the study period. The 
last month ‘active’ was the latest month with recorded 
activity in the EHR, up to the most recent record on or 
before December 31, 2012. The index event was the 
date of the first recorded Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) COPD stage [GOLD 
I (mild), GOLD II (moderate), GOLD III (severe), GOLD 
IV (very severe)] [12]. Key inclusion criteria for the 
benchmark dataset were: (a) ≥1 EHR with diagnosis of 
COPD [International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes 490.
xx, 491.xx, 492.xx, or 496.xx], occurring between Janu-
ary 1, 2007 and December 31, 2012; (b) ≥1 EHR indicat-
ing GOLD stage; (c) age ≥40 to ≤90 years on the date of 
first GOLD stage record during the study period. Addi-
tional inclusion criteria were: (d) the first (earliest) month 
active (as of receiving medical services) was before or 
the same as the month of the index date; and (e) the 
last month active (as of receiving medical services) was 
at least 12  months following the month in which the 
index date occurred. These additional inclusion criteria 
allowed a proxy eligibility period for each patient to be 
created based on the first and last months active, under 
the assumption that all healthcare was continuously 
received in the healthcare system and recorded in the 
EHR between the first and last months active.
Evaluation period and study variables
Data were evaluated for a 12-month period, starting 
from and including the index date. Patient demographics 
included age, gender, race, and geographic region. Param-
eter estimates were developed for study variables of inter-
est, which included COPD symptoms, exacerbations, 
healthcare utilization, medication, and comorbidities. 
ICD-9-CM codes were used to determine comorbidities 
[cardiovascular disease (CVD), including heart failure, 
stroke, acute myocardial infarction, and peripheral vas-
cular disease; chronic kidney disease; asthma; or depres-
sion; (Additional file 1: Table S1)]. COPD symptoms 
(shortness of breath, cough, wheezing, reduced ability 
to perform activities) were based on those reported in 
EHR notes, extracted using NLP, and classified accord-
ing to Systematized Nomenclature of Medicine–Clinical 
Terms (SNOMED-CT) [13]. Humedica’s NLP system, the 
Amplified Chart Extractor (ACE), was developed using 
vocabulary from the Unified Medical Language System 
(UMLS). This vocabulary includes multiple medical dic-
tionaries such as the SNOMED-CT, Logical Observation 
Identifiers Names and Codes (LOINC), and RxNorm, a 
listing of generic and branded drugs (among others). 
Using an architecture based on pipelines and standoff 
annotations as described in the Unstructured Informa-
tion Management Architecture (UIMA) [14], the ACE is 
similar to other UIMA based systems such as cTAKES, as 
previously described in Savova et al. [15].
Exacerbations were defined as any of the following: 
prescription for steroids and antibiotics on the same date, 
COPD-related emergency room visit, or COPD-related 
hospitalization based on discharge diagnosis. Healthcare 
resource utilization was defined as all-cause hospitali-
zation based on inpatient admissions, all-cause emer-
gency room visits with a unique service date, all-cause 
office visits with a unique service date, and medications 
for COPD. Medications of interest included inhaled cor-
ticosteroids (ICS), long-acting beta agonists (LABAs), 
ICS/LABAs, and long-acting muscarinic antagonists 
(LAMA).
Comorbidities were reported as dichotomous variables, 
coded as yes/no, and reported as a percentage. COPD 
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symptoms or exacerbations were reported as either 
dichotomous or continuous variables (coded as fre-
quency per patient and reported as mean event rate and 
standard deviation), or both. Healthcare resource utili-
zation and medication use during the follow-up period 
were reported as percentages or event rates.
Data analysis
The benchmark complete dataset of EHRs for the COPD 
cohort was created after applying all inclusion criteria, 
including the proxy eligibility period. The benchmark 
dataset provided parameter estimates for variables of 
interest, to be compared with the simulated datasets; it 
was also used to create simulated datasets with different 
amounts of missing data.
A total of 9,000 simulated datasets were created and 
analyzed. The percentage of individuals missing some of 
their EHR data was set at each 10th percentile from 10 to 
90% inclusive (nine levels, each with 1,000 datasets). To 
create cohorts with missing data, the amount of missing 
data per individual was randomly set to be between 1 and 
11 months (each patient had at least 1 month of data). For 
example, in the first group of 1,000 datasets, 10% of the 
patients would be missing some data, and the amount of 
missing data per patient would be assigned to vary ran-
domly between 1 and 11 months. A similar approach was 
applied for the remaining eight levels of missing data (that 
is, 20–90%). Patients were randomly selected via SUR-
VEYSELECT procedure in SAS 9.2 with a simple random 
sampling method without replacement. In total, there 
were 25 rounds of selections for each 10th percentile. Also 
for each patient, a random number was generated from 
the uniform distribution on the interval [1, 11] by using 
RANUNI function in SAS 9.2. This random number indi-
cates the number of months with missing data. A preset 
seed was used for each of the random selections.
For each patient, missing data were in con-
tinuous periods and were set for the period from 
[index date  +  12  months  −  X months] to [index 
date  +  12  months], where X  =  the number of miss-
ing months between 1 and 11. The last active month 
was then defined as: [month corresponding to the 
index date  +  12  months  −  X months]. For example, 
if X =  2, a patient’s records for the period from [index 
date  +  10  months] to [index date  +  12  months] were 
dropped, and the last active month was then defined as: 
[month corresponding to the index date +  10  months]. 
For each simulated dataset, the same study variables as in 
the benchmark dataset were defined and evaluated.
To assess estimator performance under increasing lev-
els of missing data, two analyses, one restricted by eligi-
bility proxy and one unrestricted, were performed on the 
9,000 datasets. For the restricted analysis, patients met 
the inclusion criteria of the first month active occurring 
before the index date, and the last month active occur-
ring at least 12 months after the index date. Sample size 
in each dataset was then decreased commensurate with 
the percentage of assigned missing data, equal to percen-
tiles between 10 and 90%. For the unrestricted analysis, 
the inclusion criteria of first/last active months were not 
applied. Thus, the unrestricted analysis assumed every-
one had 12 months of follow-up, but in reality 10–90% of 
patients would have been missing various months of fol-
low-up. We hypothesized that the results of the restricted 
analysis, for which the eligibility proxy would reduce the 
amount of missing data, would be less biased than those 
from the unrestricted analysis.
Estimate evaluation criteria
One thousand sample datasets were developed for each 
of the nine levels of percentiles. Estimates for each 
study variable (θˆ) were compared with those from the 
benchmark dataset (θ), which had no missing data and 
12  months of follow-up after the index date. The qual-
ity of the parameter estimates (that is, estimate per-
formance) for each variable was evaluated using bias, 
percentage change, and root-mean-square error (RMSE), 
and was compared with the quality of estimates for the 
benchmark dataset. Each of these measures provides a 
different type of information about estimator perfor-
mance, as shown by their definitions below.
Bias of an estimator θˆ of a parameter θ was defined as
Variance of an estimator θˆ of a parameter θ was defined 
as
Root-mean-square error is the square root of mean 
squared error (MSE), and denotes the average of the 
squares of the difference between the estimator and the 
estimated parameter. RMSE of an estimator θˆ of a param-
eter θ was defined as
All data analyses were conducted in SAS version 9.3 
(SAS Institute Inc., Cary, NC, USA).
Results
Data characteristics
Within the EHR database, 700,318 patients had an ICD-
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and first/last month active criteria, the final sample size 
of the benchmark complete dataset was 6,717 (Figure 1). 
Figure 2 showed the process of creating 1,000 simulated 
datasets for random 10% of patients having missing 
records as an example and sample sizes for restricted and 
unrestricted analysis. The same process was applied to 
each 10th percentile from 20 to 90%. For the unrestricted 
analysis, all sample sizes were the same as the benchmark 
dataset, regardless of the proportion of missing data 
specified. In the restricted analysis, sample sizes ranged 
from 6,045 with 10% of patients having missing records 
to 671 with 90% with missing records (Table  1). In the 
benchmark dataset, mean age was 69  years (standard 
deviation (SD) 10.7; Table 2) and median age was 70 years 
(interquartile range 15  years). Asthma, chronic kidney 
disease, CVD, and depression were common comorbidi-
ties occurring in at least 10% of the sample, and 19.3% of 
patients had exacerbations within the 12-month follow-
up period (Table 2).
Bias with missing data
In the restricted analysis, in which inclusion criteria for 
first/last month active were applied, parameter estimates 
showed very small or almost no bias compared with 
benchmark data for each variable investigated (Figure 3). 
However, the variance (spread) in bias increased (y-axis) 
due to a decrease in the restricted sample size as the per-
centage of individuals with missing data increased from 
10 to 90% (x-axis). In comparison, for the unrestricted 
analysis, where the first/last active month requirement 
was not applied, all parameter estimates were system-
atically underestimated, as shown by an increase in the 
(negative) magnitude of bias (Figure  3). The differences 
between estimates from the unrestricted and restricted 
analyses became more pronounced as the percentage of 
patients with missing data increased, as shown on the 
graphs by the increasing separation in bias between the 
two sets of results.
Specific examples of the consequences of missing data
The consequences of increased bias also were dem-
onstrated in several examples using different patient 
descriptors and outcomes. The first was the percentage of 
patients with CVD, which was 32.5% in the benchmark 
dataset. Among those with CVD, mean bias was similar 
in the restricted analysis when evaluated for 10, 50, and 
90% of patients missing data, with mean bias of <0.1, 0, 
and 0.2%, respectively (Figure  3a). In contrast, for the 
unrestricted analysis, mean bias increased with increas-
ing amounts of missing data (−1, −5.1, and −9.3% cor-
responding to 10, 50, and 90% of patients missing data, 
respectively).
The second example pertained to individuals with 
shortness of breath: 63.8% of the cohort had ≥1 occur-
rence in the 12-month follow-up period (mean 3.48 
occurrences per person; SD 5.48). In the restricted analy-
sis, mean bias in the estimated percentage of individuals 
with an occurrence was <0.1% in samples with 10% as 
well as with 90% of individuals having missing data; in 
the unrestricted analysis, mean bias was −0.6% for the 
10% missing data cohorts and increased in magnitude to 
−5.4% for those with 90% missing data (Figure  3b). For 
the mean number of occurrences of shortness of breath 
per patient, mean bias in the restricted analysis was 0.004 
and 0.026 in samples with 10 and 90% of individuals miss-
ing data (respectively); in the unrestricted analysis, the 
corresponding values were −0.138 and −1.25 (Figure 3c).
Bias patterns similar to those for CVD and shortness 
of breath were seen for the percentage of patients with 
ICS/LABA use (Figure 3d) and with an exacerbation (Fig-
ure 3f ). Mean bias in the restricted analysis varied little 
according to the amount of missing data, while mean 
bias in the unrestricted analysis was larger and increased 
with the percentage of missing data. With respect to fre-
quency of ICS/LABA use (Figure  3e) or exacerbations 
(Figure  3g), both of which were relatively rare, differ-
ences in bias were smaller between the unrestricted and 
restricted analyses.
The final example examined bias in an even rarer event, 
all-cause hospitalization. In the benchmark dataset, 8.9% 
of the population had ≥1 hospitalization, with a mean 
of 0.15 (SD 0.56) hospitalizations per patient during the 
12-month follow-up period. For the dataset with 10% 
Include patients had at least one gold stage I, II, III or IV,
keep the date of first gold stage as index date
N = 9,316
Benchmark Data
First active month must be prior to or the same as 
the index date and last active month must be 
at least 12-month post the index date
N = 6,717
40 ≤ Age ≤ 90 on the index date
N = 9,054
Patients with any of the following ICD9 codes 
490.xx, 491.xx, 492.xx, 496.xx in the database
N = 700,318
Figure 1 Patient attrition and cohort selection. Inclusion and exclu‑
sion criteria show cohort selection for the benchmark data set.
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of patients missing data, the mean bias in the estimated 
proportion of individuals hospitalized at least once was 
<0.1% in the restricted analysis and −0.29% in the unre-
stricted analysis (Figure  3h). For this same dataset, bias 
in the mean number of hospitalizations per patient was 0 
for the restricted analysis and −0.006 for the unrestricted 
analysis (Figure 3i). In the dataset with 90% of individuals 
missing records, the bias in the percentage of individuals 
Benchmark Data
First active month must be prior to or the same as 
the index date and last active month must be 
at least 12-month post the index date
N = 6,717
Round 1
Among N = 6,717, 
randomly selected 672 individuals 
Sample Data 1
Among N = 6,717, 
random number of 
months with missing data 
was set for each selected 
672 individuals
Restricted analysis














N = (6,717 – 672) = 6,045
Sample Data 40
Among N = 6,717,
random number of 
months with missing data 
was set for each selected 
672 individuals
Round 25
Among N = 6,717, 
randomly selected 672 individuals  
Omitted
Figure 2 Simulation datasets creating process. An example of how the simulation datasets were derived among random 10% of patients having 
missing records.
Table 1 Characteristics of the datasets used in the unrestricted and restricted analyses
Percentage with  
missing data
Unrestricted analysis Restricted analysis
N Mean (SD) months of data N Mean (SD) months of data
10% 6,717 11.4 (0.01) 6,045 12 (0)
20% 6,717 10.8 (0.02) 5,373 12 (0)
30% 6,717 10.2 (0.02) 4,701 12 (0)
40% 6,717 9.6 (0.02) 4,030 12 (0)
50% 6,717 9.0 (0.03) 3,358 12 (0)
60% 6,717 8.4 (0.03) 2,686 12 (0)
70% 6,717 7.8 (0.03) 2,015 12 (0)
80% 6,717 7.2 (0.04) 1,343 12 (0)
90% 6,717 6.6 (0.04) 671 12 (0)
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with a hospitalization was 0.4% for the restricted analy-
sis and −2.7% for the unrestricted analysis. Bias in the 
estimated mean number of hospitalizations per patient 
was 0.004 for the restricted analysis and −0.057 for the 
unrestricted analysis. The magnitude of the bias for rare 
events, such as the percentage with a hospitalization or 
the mean number of hospitalizations per patient, was 
smaller than for more prevalent variables such as the per-
centage with shortness of breath (Fig. 3b, c) or with ICS/
LABA use (Fig. 3d, e).
Bias provides one measure of estimate performance. 
With respect to the unrestricted analysis, the observed 
low bias for hospitalization frequency estimates with 90% 
missing data did not necessarily mean that outcome esti-
mates for rare events (such as hospitalization) were more 
accurate than those for more frequent events. Therefore, 
we also assessed estimate performance using other meas-
ures, such as percentage change and RMSE.
Percentage change and RMSE with missing data
Additional information about the performance of param-
eter estimates was provided by using percentage change 
(Figure  4) and RMSE (Additional file 2: Figure S1). The 
percentage change between parameter estimates in the 
benchmark dataset and missing datasets for rare events 
was larger than for more frequently occurring events. For 
the frequently occurring event of at least one episode of 
shortness of breath (63.8% in the benchmark dataset), the 
percentage change observed in the datasets with 90% of 
patients missing some data from benchmark estimates 
was relatively small, at 0.01% in the restricted analysis 
and −8.47% in the unrestricted analysis (Figure  4a). In 
contrast, for patients with ≥1 hospitalization, a relatively 
rare event (8.9% in the benchmark dataset), the percent-
age change in the estimate for the 90% missing dataset 
from that for the benchmark dataset was 4.40% in the 
restricted analysis and −30.14% in the unrestricted anal-
ysis (Figure 4c).
For frequency variables, when the magnitude of the 
estimate was small (as for rare events), such as for the 
mean number of occurrences of shortness of breath 
per patient, the percentage change in the parameter 
estimates in the unrestricted analysis was large. In the 
dataset with 90% of patients missing data, the percent-
age change from the benchmark dataset in the mean 
number of shortness of breath episodes per patient 
was 0.73% for the restricted analysis and −35.87% for 
the unrestricted analysis (Figure  4b). The percentage 
change in mean number of hospitalizations per patient, 
also a rare event, showed a similar increase from the 
benchmark dataset in the unrestricted analysis as the 
percentage of patients missing data increased (Fig-
ure  4d). RMSE for parameter estimates demonstrated 
patterns similar to those for percentage change (Addi-
tional file 2: Figure S1).
Discussion
Using a cohort of patients with COPD identified in a 
large EHR, we created multiple simulated datasets of 
COPD patients with differing amounts of missing data to 
assess the utility of a proxy eligibility period. We found 
that parameter estimates had better performance when 
an eligibility proxy based on the first and last month 
Table 2 Characteristics of benchmark cohort
Variable N (%) Mean (SD)
Sample size, final 6,717 (100)
Age (years) 69 (10.7)
Gender
 Female 3,319 (49.4)
 Male 3,398 (50.6)
Race
 Caucasian 5,783 (86.1)
 African American 180 (2.7)
 Asian 31 (0.5)
 Other/unknown 723 (10.8)
US region
 Midwest 3,956 (58.9)
 South 1,529 (22.8)
 West 878 (13.1)
 Northeast 173 (2.6)
 Other/unknown 181 (2.7)
Outcomes in the 12 months post index
 Comorbidity
  Asthma 1,536 (22.9)
  Chronic kidney disease 840 (12.5)
  Cardiovascular disease 2,186 (32.5)
  Depression 851 (12.7)
 COPD medication of interest
  Inhaled corticosteroid 937 (13.9) 0.21 (0.6)
  Inhaled corticosteroid/long‑acting beta 
agonists
2,832 (42.4) 0.72 (1.08)
  Long‑acting beta agonists 226 (3.4) 0.05 (0.3)
  Long‑acting muscarinic antagonists 2,219 (33.0) 0.53 (0.93)
 COPD‑related symptoms
  Cough 3,958 (58.9) 2.93 (5.49)
  Reduced ability to perform activities 2,166 (32.2) 1.07 (3.13)
  Shortness of breath 4,284 (63.8) 3.48 (5.48)
  Wheezing 2,931 (43.6) 1.47 (3.11)
 Exacerbations 1,296 (19.3) 0.3 (0.78)
 All‑cause resource utilization
  Emergency room visit 583 (8.7) 0.17 (0.78)
  Hospitalization 596 (8.9) 0.15 (0.56)
  Office visit 5,464 (81.3) 9.5 (11.12)
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Restricted analysis
Unrestricted analysis
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of observed database activity (restricted analysis) was 
applied. This finding was consistent across a range of 
variables including patient comorbidities, symptoms, 
outcomes, health resource utilization, and medications, 
regardless of the measures of performance used (that is, 
bias, percentage change, and RMSE). For the unrestricted 
analysis, in which the eligibility proxy was not applied, all 
evaluated parameters were consistently underestimated.
In the unrestricted analysis, bias consistently increased 
as the proportion of patients with missing data increased, 
yet for many variables evaluated in the unrestricted analy-
sis, the magnitude of bias was relatively low. For dichoto-
mous variables (reported as percentages), bias was often 
less than 5%, and for continuous variables (reported as 
frequencies), bias was often less than one unit, even with 
up to 90% of patients missing some data. Consequently, 
the minimal observed bias can be a misleading indicator of 
estimate performance. Estimates using other performance 
measures, such as percentage change from benchmark 
estimates, showed that performance could still be poor 
(see figure on previous page)
Figure 3 Bias in parameter estimates. Box plots of the bias in selected parameter estimates by percentage of individuals with missing data for the 
restricted analysis and the unrestricted analysis. a Percentage of patients with cardiovascular disease, b percentage of patients experiencing short‑
ness of breath, c mean number of shortness of breath occurrences per patient, d percentage of patients prescribed ICS/LABA, e mean number of 
ICS/LABA prescriptions per patient, f percentage of patients with an exacerbation, g mean number of exacerbations per patient, h percentage of 
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Figure 4 Percentage change in parameter estimates. Box plots of percentage change in selected parameter estimates by percentage of patients 
with missing data for the restricted analysis and the unrestricted analysis. a Percentage of patients experiencing shortness of breath, b mean 
number of shortness of breath occurrences per patient, c percentage of patients with a hospitalization, and d mean number of hospitalizations per 
patient.  
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even if bias was low. These findings illustrate that more 
than one measure is needed to evaluate estimate perfor-
mance because different measures reflect different types 
of performance. For example, bias is particularly sensi-
tive to the number of events and thus can be problematic 
for describing estimate performance for rare events. This 
is because a rare event occurring during the missing data 
period reflects a greater proportion of missing data than 
a more frequent event, resulting in a greater percentage of 
underreporting than for a more common event.
This study is unique in that it provides an easily imple-
mented method to minimize the impact of missing data 
and to improve the accuracy of parameter estimates 
when using EHR data in outcomes research. EHRs are 
attractive for outcomes research because, in addition to 
healthcare and drug utilization and outcomes data, they 
provide useful information not available in many admin-
istrative claims databases, such as biometrics, symptoms, 
and laboratory results. However, unlike claims databases, 
EHRs lack eligibility tables (plan enrollment information) 
and thus are subject to surveillance bias due to missing 
data. Researchers can address the problem of missing 
data by applying an eligibility proxy based on the earliest 
and latest months of recorded activity in the EHR.
This study is limited by assumptions made when apply-
ing the eligibility proxy and by features of EHR datasets. 
It was assumed that records within the eligibility period 
identified by the eligibility proxy (first/last month active) 
were complete. That is, all medical services a patient 
received during this time period identified by the eligi-
bility proxy were recorded in EHR datasets. In addition, 
the accuracy and completeness of the EHRs used in this 
study are not known. Events may not have been recorded 
if individuals were not asked about these specifically, or if 
providers did not document these when reported. Some 
diagnoses and treatments may have been coded incor-
rectly. Although prescriptions for medications may have 
been documented, it is not known whether the prescrip-
tions were filled or taken. Moreover, the number of refills 
may not have been noted. A limitation inherent to EHR 
data is the potential for incomplete information, particu-
larly if healthcare was received outside the EHR system. 
Missing encounter data (including underreporting by 
patients or providers) between the first month active and 
the last month active may have resulted in systematic 
underestimation of events and healthcare resource utili-
zation in the benchmark dataset. This limitation would 
apply to any EHR study and is not unique to this US-
based EHR dataset used in this study.
Conclusion
In this simulation study of a COPD cohort identified in 
a large US-based EHR, we demonstrated the benefits of 
applying an eligibility proxy using information readily 
available in the EHR (first and last month of observed 
activity) when conducting outcomes research with 
these types of data. The simulation showed that, when 
an eligibility proxy was applied and the analysis was 
restricted to patients with sufficient follow-up time 
based on this proxy, estimates for a range of variables of 
interest had very low or no discernible bias. The benefit 
of applying an eligibility proxy became more evident as 
the percentage of missing data increased. When pos-
sible, researchers using EHRs should include a proxy 
eligibility period to increase the likelihood of having a 
complete EHR for the study period, in turn reducing 
surveillance bias.
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